Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.

PLoS One · 2016 · PMC4911003 · PMID 27308831

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The OS also was increased with chemohormonal therapy compared with ADT alone, but the difference did not reach statistical significance (ADT plus docetaxel: median 62.1 versus 48.6 months for ADT alone, HR 0.88, 95% CI 0.68–1.14) ( Table 3 ); In an unplanned subset analysis, there was no difference in OS for subgroups with low and high-volume disease.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.